Main Article Content
Objective: To evaluate the safety and efficacy of percutaneous transvenous mitral commissurotomy (PTMC) via patent foramen ovale (PFO) in patients with severe mitral stenosis (MS).
Material and MethodsL All patients underwent trans-thoracic and trans-esophageal echocardiogram before PTMC. Patent foramen ovale was probed with assembly pointing posteriorly, a little below aortic valve in lateral view. If access to the left atrium could not be gained, transeptal puncture with Bronkenbrough needle was performed and the rest of the PTMC performed with standard Inoue balloon.
Results: Out of 500 patients 370 (64%) were females and 130 (36%) were males. The mean age was 27.51+ 7.82 years. PFO was probed and crossed in 435/500 (87%) patients. All PFO's were crossed within 15 + 04 minutes of commencement of probing. Spending a longer time searching for PFO did not increase the yield. Mean valve area was 0.86 + 0.19 cm
immediately after PTMC (p <0.05). The mean mitral valve gradient decreased from 17 + 4.04 mmHg to 6.8 + 0.25 mmHg immediately after PTMC (p <0.005). No pericardial effusion/tamponade observed in PFO group. The time to cross mitral valve was significantly reduced while accessing through PFO as compared to interatrial septal puncture.
Conclusion: PTMC performed via patent foramen ovale is safe. It associated reduces the time of the procedure and complications.2, which increased to 1.86 + 0.17 cm2
Work published in JPMI is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.